Cargando…
Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
Greater understanding of the underlying etiology and biology of breast cancer is enabling the clinical development of targeted therapies for metastatic breast cancer (MBC). Following the successful introduction of trastuzumab, the first human epidermal growth factor receptor (HER) biologically targe...
Autores principales: | Rosen, Lee S., Ashurst, Helen Louise, Chap, Linnea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227950/ https://www.ncbi.nlm.nih.gov/pubmed/20200040 http://dx.doi.org/10.1634/theoncologist.2009-0145 |
Ejemplares similares
-
Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2010) -
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
por: Extra, Jean-Marc, et al.
Publicado: (2010) -
Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
por: Sherrill, Beth, et al.
Publicado: (2010) -
Effect of Patient Age on Management Decisions in Breast Cancer: Consensus from a National Consultation
por: Leonard, Robert C., et al.
Publicado: (2010) -
Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
por: Aggarwal, Rahul, et al.
Publicado: (2011)